Novo Nordisk

Page 4 of 9

Lars Fruergaard Jorgensen, chief executive officer Novo Nordisk A/S, during an interview at the company's headquarters in Bagsvaerd, Denmark, on Monday, June 12, 2023.
Health

Novo Nordisk CEO takes aim at U.S. healthcare as he defends Ozempic pricing to Bernie Sanders

By
September 24, 2024
Novo Nordisk’s $570 billion valuation is more than Denmark’s GDP—but PM isn’t worried about a ‘Nokia risk’
Finance

Novo Nordisk’s $570 billion valuation is more than Denmark’s GDP—but PM isn’t worried about a ‘Nokia risk’

By Sara Sjolin, Sanne Wass, Oliver Crook and Bloomberg
September 23, 2024
Roche stock is falling after report its Wegovy challenger is causing patients to vomit
Health

Roche stock is falling after report its Wegovy challenger is causing patients to vomit

By Naomi Kresge and Bloomberg
September 12, 2024
Ozempic maker has developed a pill that can cause weight loss of up to 13% in three months
Health

Ozempic maker has developed a pill that can cause weight loss of up to 13% in three months

By
September 11, 2024
Half of Denmark’s GDP growth in 2024 will be thanks to Novo Nordisk, analysts predict
Tech

Half of Denmark’s GDP growth in 2024 will be thanks to Novo Nordisk, analysts predict

By Sanne Wass and Bloomberg
September 3, 2024
A photo of the packet for anti-obesity drug Wegovy.
Health

Wegovy reduced Covid deaths in obese patients, study finds

By Madison Muller and Bloomberg
August 30, 2024
A person sifts through a rack of clothing.
Retail

Secondhand luxury fashion thrives as Ozempic users purge their closets

By
August 29, 2024
Novo Nordisk’s weight-loss drugs and Bavarian Nordic’s mpox vaccine help fatten up the Danish economy
Finance

Novo Nordisk’s weight-loss drugs and Bavarian Nordic’s mpox vaccine help fatten up the Danish economy

By Sanne Wass and Bloomberg
August 20, 2024
Norway’s $1.7 trillion wealth fund made billions from tech in 2024—now it’s slashing its stake in Meta, Novo Nordisk and ASML
Finance

Norway’s $1.7 trillion wealth fund made billions from tech in 2024—now it’s slashing its stake in Meta, Novo Nordisk and ASML

By Kari Lundgren and Bloomberg
August 14, 2024
Here’s the real reason Ozempic-like weight-loss drugs are so popular
Commentary

Here’s the real reason Ozempic-like weight-loss drugs are so popular

By
August 12, 2024
An Ozempic (semaglutide) injection pen is seen on a kitchen table.
Health

How Denmark got homegrown giant Novo Nordisk to lower Ozempic prices

By Arthur Allen and KFF Health News
August 7, 2024
Lars Fruergaard Jorgensen, chief executive officer of Novo Nordisk, speaks during a Bloomberg Television interview in New York, US, on Wednesday, Aug. 10, 2022. Two more factories will begin producing Novo Nordisk A/S's obesity medication Wegovy next year after manufacturing issues and high demand left the drug in short supply, Jorgensen said. Photographer: Christopher Goodney/Bloomberg via Getty Images
Retail

Europe’s most valuable company Novo Nordisk reports an uptick in profits as demand for weight-loss drugs continues to grow

By
August 7, 2024
In this year’s Global 500 list: Energy woes, retail gains, and boom times for AI and weight-loss drugs
Newsletters

In this year’s Global 500 list: Energy woes, retail gains, and boom times for AI and weight-loss drugs

By
August 5, 2024
Angela Fitch. cofounder and chief medical officer of knownwell.
Commentary

I’m an obesity medicine doctor and I’ve been on weight-loss drugs like Ozempic for a decade. Here’s why I think they aren’t a fad

By
July 30, 2024
Thomas Schinecker, chief executive officer of Roche
Finance

Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss

By
July 29, 2024

Most Popular